Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VGHBPH0 is a Chinese herbal medicine (CHM) formula developed as an adjunct treatment for benign prostatic hyperplasia (BPH) and lower urinary tract symptoms. The formula consists of a combination of traditional Chinese medicinal ingredients, specifically Ji-Sheng-Shen-Qi-Wan, Sang-Piao-Xiao-San, Wu Yao, Yi Zhi Ren, Dan Shen, Yin Yang Huo, Fu Pen Zi, Huang Bo, and Zhi Mu. Clinical studies suggest that VGHBPH0 may improve BPH-related symptoms such as reducing the International Prostate Symptom Score (IPSS) and post-voiding residual urine volume when used alongside standard Western therapies like α1-blockers. The mechanism of action is presumed to be multi-targeted modulation of urinary tract function and inflammation based on the known properties of its herbal components[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on VGHBPH0.